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use#LAAIn 1990, with the initial launch of a 15-year project to 
map  and  sequence  the  human  genome,  a  new  era  of 
science  began.  However,  even  after  its  successful  and 
early completion in 2001 [1], no one could have foreseen 
how, only a few years later, genome sequencing would 
explode to become a widely applied multi-purpose tool 
whose  applications  include  the  mapping  of  epigenetic 
modifications  and  the  complete  assessment  of  both 
coding  and  non-coding  RNA  transcripts.  The  game 
changer  behind  this  explosion  was  the  transition  from 
the  classic  electrophoretic  Sanger  sequencing  method, 
which had limited scalability, to image-based massively 
parallel ‘sequencing-by-synthesis’ platforms.
It  had  already  become  clear  in  the  early  days  of  the 
post-genome  era,  before  these  technological 
breakthroughs, that there were additional layers to the 
primary sequence waiting to be uncovered, and a small 
number  of  pilot  epigenome  projects,  including  the 
Human  Epigenome  Consortium  (HEC),  were  launched 
[2,  3].  While  on  the  right  track,  these  early  projects 
suffered from lacking the sequencing capacity required to 
tackle the multidimensional space of the epigenome. This 
obstacle was overcome in 2006, with the introduction of 
next generation sequencing platforms, and the NIH was 
commendably fast to capitalize on these developments by 
implementing  both  its  ENCODE  and  ‘Roadmap 
Epigenomics’  projects.  ENCODE  aimed  to  utilize  the 
newly generated epigenome maps to assist in discovering 
and assigning functional elements in the genome, while 
the  Roadmap  Epigenomics  Program  aimed  to  create 
reference maps for the majority of normal, primary cell 
types [4, 5]. The success of these projects has helped to 
popularize  epigenomics  and  has  proved  somewhat 
contagious,  with  additional  consortia,  such  as  the 
recently  funded  BLUEPRINT  (European)  and  DEEP 
(German),  arriving  on  the  scene;  the  International 
Human Epigenome Consortium (IHEC) now coordinates 
international efforts.
The core technologies used in these projects, and in 
general across the field, have stabilized over the years and 
standards  are  now  largely  agreed  upon.  Chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) 
[6,  7]  remains  the  standard  assay  for  determining 
transcription factor binding, as well as for mapping the 
genome-wide  distribution  of  histone  modifications. 
Continued efforts to increase sensitivity and resolution 
has resulted in some recent technical improvements to 
the basic ChIP-seq method, in the form of nano-ChIP-
seq  [8]  and  ChIP-exo  [9],  respectively.  By  contrast, 
dozens  of  assays  exist  for  DNA  methylation  [10], 
although most genome-wide studies are focused on just a 
few  of  these  [11-13].  As  costs  continue  to  decrease, 
methods  are  converging  on  whole  genome  bisulfite 
sequencing [14], which had previously been prohibitively 
expensive.  As  with  exome  sequencing,  the  subject  of 
Genome  Biology’s  2011  special  issue  [15],  the  driving 
force behind the ongoing explosion in epigenome studies, 
and data, has been an increase in sequencing capacity at 
reduced cost.
What can epigenomics do for you?
Epigenome  data  are  very  powerful  and  have  multiple 
applications  that  extend  beyond  a  simple  map  of  a 
particular  mark  or  modification  in  a  given  cell  type. 
Below, I will highlight a few selected examples of these 
applications, although this is a far from exhaustive list.
Genome Annotation
Mammalian  genomes  are  large  and  complex. 
Understanding  such  genomes  is  not  trivial  and 
comparative  genomics  based  on  the  primary  DNA 
sequence alone, while powerful [16], cannot provide all 
the answers. As demonstrated several years ago [7], and 
further  highlighted  by  the  many  recent  ENCODE 
publications  [17],  chromatin  signatures  enable  efficient 
and precise genome annotation of regulatory elements, 
and can pinpoint functional or cell type-specific regions 
of interest.
Cell identity
It has become abundantly clear over the past years that 
epigenomic maps provide more information than can be 
gained  from  gene  expression  data  alone  [6,  7,  18-20].  © 2010 BioMed Central Ltd
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can  add  further  refinement  to  a  gene’s  activity  status, 
such  as  whether  it  is  primed  or  poised,  and  can  also 
describe varying degrees of repressed states that would 
all look the same by any gene expression measure. The 
precise  chromatin  state  of  these  loci  can  have  clear 
consequences  for  how  they  behave  in  both  normal 
development and disease.
Disease
As  highlighted  by  many  studies  of  human  disease, 
including several in this issue [21-27], epigenomic maps 
can be utilized to trace the origin of cells, dissect effected 
pathways and identify predictive biomarkers. Epigenome 
data  have  also  proved  to  be  powerful  in  helping  to 
pinpoint  disease-relevant  regulatory  elements  through 
epigenome-wide  association  studies,  or  ‘EWAS’, 
especially when integrated with data from genome-wide 
association studies [17, 28].
Challenges
Several  of  the  reports  in  this  special  issue  expand  the 
catalog  of  user-friendly  tools  for  the  visualization  of 
epigenomic  datasets  [27,  29-31],  and  much  work  has 
previously  been  done  elsewhere  in  this  area,  including 
the development of advanced epigenome browsers [32, 
33]. Making data even more accessible will be critical if 
the field is to continue its rapid growth and strengthen its 
impact.  As  the  number  of  epigenomic  datasets  grows 
into  the  thousands  and  tens  of  thousands,  of  key 
importance will be plans made to ensure that sufficient 
standards are met and that data can be navigated in well 
curated, high quality databases. An additional challenge 
in data integration is that much of the full complexity of 
the  epigenome  lies  in  uncharted  waters,  with  many 
known  modifications  remaining  unmapped  and  other 
modifications, such as hydroxylmethylation [34], moving 
to the center stage. This dynamism in the types of data 
being  produced  will  be  sure  to  generate  increasing 
demands for new, refined, bioinformatic tools.
Conclusions
The overall impact of the growing number of epigenomes, 
including  the  NIH  Roadmap  Epigenomics  Project 
reference  maps,  will  likely  be  underestimated.  For 
example, almost every study uses the reference genome 
sequence,  whether  it  is  to  design  primers,  target 
constructs or align sequencing reads, yet those studies 
rarely acknowledge the reference genome, because it is 
simply there and so you can just use it.
I  predict  that,  as  investigators  become  more 
accustomed to epigenome browsers and to utilizing the 
existing data for various purposes, the reference set of 
epigenomics maps will also become a routine resource 
used  in  many  studies.  Applications  would  include 
providing a quick overview of a gene/locus of interest; 
helping to refine a hypothesis; assisting primer design by 
narrowing down the exact region of dynamic regulation; 
forming  the  bases  of  reporter  assays  by  selecting  with 
precision the functional elements of an upstream regions; 
and so forth.
This special issue covers epigenomics over a wide range 
of organisms, systems and methods, all of which provide 
an informative sampling to illuminate the possibilities for 
future studies in this expanding and exciting field.
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